ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Monday, November 8, 2021

2:15PM-2:30PM: Abstract Number: 1447

Long-Term Effect of Prescription Non-Steroidal Anti-Inflammatory Drug Regular Use on the Risk of a Knee Replacement

Abstracts: Clinical Epidemiology (1446–1451)

2:15PM-2:30PM: Abstract Number: 1443

Long-term Effectiveness of Ultra-Low Doses of Rituximab in Rheumatoid Arthritis

Abstracts: RA – Treatments II: New Findings in Established Therapies (1442–1445)

2:30PM-2:45PM: Abstract Number: 1444

Baseline Factors Associated with the Development of Nausea and Alopecia over One Year in Patients Starting Methotrexate for Rheumatoid Arthritis

Abstracts: RA – Treatments II: New Findings in Established Therapies (1442–1445)

2:30PM-2:45PM: Abstract Number: 1440

Targeting Endogenous Mesenchymal Stromal Cell Response to Interferong in Sjӧgren’s Syndrome

Abstracts: Cytokines & Cell Trafficking (1438–1441)

2:30PM-2:45PM: Abstract Number: 1448

Virtual Visits versus Face-to-Face Visits for Rheumatoid Arthritis (RA): Comparison of Treat to Target (TTT) Adherence in 18 US Rheumatology Practices

Abstracts: Clinical Epidemiology (1446–1451)

2:45PM-3:00PM: Abstract Number: 1445

Association Between Baseline Use of Rituximab and COVID-19 Outcomes in Patients with Rheumatoid Arthritis (RA)

Abstracts: RA – Treatments II: New Findings in Established Therapies (1442–1445)

2:45PM-3:00PM: Abstract Number: 1449

Is Repeat Serum Urate Testing Superior to a Single Test to Predict Incident Gout over Time?

Abstracts: Clinical Epidemiology (1446–1451)

2:45PM-3:00PM: Abstract Number: 1441

Pharmacological Characterization of GLPG3667, a Selective TYK2 Inhibitor for Treatment of Inflammatory Diseases

Abstracts: Cytokines & Cell Trafficking (1438–1441)

3:00PM-3:15PM: Abstract Number: 1450

Unsupervised Machine Learning Methods to Cluster Comorbidities in a Population-based Cohort of Patients with Rheumatoid Arthritis

Abstracts: Clinical Epidemiology (1446–1451)

3:15PM-3:30PM: Abstract Number: 1451

Improving Health Outcomes and Social Connectedness Through Virtual Exercise Programs in Community Members with Musculoskeletal Conditions

Abstracts: Clinical Epidemiology (1446–1451)

3:30PM-3:45PM: Abstract Number: 1452

COVID-19 Infection Among Autoimmune/Auto-inflammatory Rheumatic Disease Patients: Data from an Observational Study

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases: New Insights into Therapies & Mechanisms of Disease (1452–1457)

3:30PM-3:45PM: Abstract Number: 1458

Sustained Efficacy and Safety of Iberdomide to Week 52 in Patients with Active Systemic Lupus Erythematosus (SLE) in a Phase 2, Randomized, Placebo-Controlled Study

Abstracts: SLE – Treatment: New Agents, Old Agents (1458–1463)

3:45PM-4:00PM: Abstract Number: 1459

Attainment of the Lupus Low Disease Activity State in Response to Anifrolumab in 2 Phase 3 Trials

Abstracts: SLE – Treatment: New Agents, Old Agents (1458–1463)

3:45PM-4:00PM: Abstract Number: 1453

Lung Interleukin-33 Is Elevated in Rheumatoid Arthritis-Associated Lung Disease

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases: New Insights into Therapies & Mechanisms of Disease (1452–1457)

4:00PM-4:15PM: Abstract Number: 1464

Ambulatory Fetal Heart Rate Monitoring (FHRM) to Surveil Pregnancies at Risk for Congenital Heart Block

Abstracts: Reproductive Issues in Rheumatic Disorders (1464–1467)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].